Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will consider this week whether seven unapproved peptides should be added to the Section 503A Bulk Drug […]
FDA Advisory Committee to weigh whether to expand compounding of unapproved peptides Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
Researchers utilize health data to inform medical breakthroughs, but patients need to know their personal information stays confidential. The current patchwork of state laws
House hearing to examine bill balancing data privacy and R&D needs Read More »
The Administration’s Council of Economic Advisors (CEA) has released an analysis of savings expected from its “Most Favored Nation” deals with pharmaceutical manufacturers, but
Exaggerated MFN cost-saving estimates imperil U.S. innovation and investment Read More »
Ohio’s diverse biotech sector provides the state with employment for 65,000 and provides the world with medical breakthroughs. Of the first eight gene therapies
BIO on the American Road tours gene therapy hub in Ohio Read More »
As biotech celebrates its 50th year, we are locked in “the fight of our lives” to ensure patients get more of the medical innovations
At some point in our lives, many of us will find ourselves in a health fight we didn’t expect. A diagnosis. A test result.
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
Voters see a better path than Most Favored Nation to ensure access and affordability of innovative medicines Eight in 10 American voters would be
Poll: U.S. voters want PBM and insurance reform—and strong biotech Read More »
Known as “America’s Medicine Cabinet,” Puerto Rico is working to maintain its leadership in U.S. biotech production by becoming a hub for reshoring pharmaceutical
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ ready to reshore Read More »
